Home / Treatments / Wearable Cardio Defib
Wearable Cardio Defib denials: what the review data shows
Independent reviewers have decided 53 published cases where an insurer denied Wearable Cardio Defib — and they overturned the insurer 64.2% of the time. A denial for Wearable Cardio Defib is a starting position, not a final answer.
Published decisions
53
2001–2026
Overturned
64.2%
34 denials reversed
Conditions behind wearable cardio defib denials
What insurers denied — and how those fights ended.
| Category | Decisions | Overturned |
|---|---|---|
| Cardiomyopathy | 22 | 63.6% |
| Congestive Heart Failure | 7 | 71.4% |
| Arrhythmia Irregular Heart Rhythm | 6 | 50% |
| Heart Attack | 6 | 83.3% |
| Cardiac Heart Prob | 5 | 40% |
What the insurer actually argued
Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
| Reason given | Decisions | Overturned |
|---|---|---|
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 46 | 67.4% |
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 7 | 42.9% |
Typical time to a decision
21 days
Most land between 11 and 21 days
Handled as urgent
17%
Expedited when a delay would cause harm
Recent direction
Rising
68.2% → 72% overturned, last three years
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested reimbursement and prospective authorization and coverage for Zoll LifeVest. Primary prevention implantable cardioverter-defibrillator (ICD) is recommended to prevent sudden cardiac arrest (SCA) and death due to ventricular tachycardia/fibrillation (VT/VF) in patients with heart failure and left ventricular ejection fraction (LVEF) of less than 36% only after a minimum of three months of guideline-directed medical therapy (GDMT). Several studies have examined whether wearable cardioverter-defibrillator (WCD) offers protection against SCA/death during these three months where GDMT is prescribed and titrated.
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for a wearable cardioverter defibrillator (automatic external defibrillator with integrated electronic cardiogram analysis, garment type). This patient has non-ischemic cardiomyopathy (NICM) and given his son’s condition and course, genetic testing has been performed to determine a causative etiology and to direct clinical prognosis, with results pending. As no other etiology of NICM is evident, it may be presumed that this patient has titin (TTN)-related NICM until results of genetic testing become available. While patients with NICM are at increased risk of arrhythmic sudden death, patients with TTN-related cardiomyopathy appear to be at especially high risk for life-threatening rhythm disturbances.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
The enrollee requested authorization and coverage, and reimbursement, for an automatic external defibrillator, with integrated electronic cardiogram analysis, garment type. The enrollee was admitted acutely on with new-onset, severe left ventricular dysfunction with fluid overload. The enrollee has longstanding left bundle branch block and no evidence of coronary artery disease or acute myocarditis. Cardiology indicated the enrollee can switch from angiotensin-converting enzyme inhibitors to angiotensin II receptor blockers to allow for a transition to Entresto if needed, and to minimize the side effect of cough. The enrollee was discharged home with an automatic external defibrillator due to being considered high risk for sudden cardiac arrest.
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested reimbursement for a heart monitor. In this case, if cardiac monitoring were thought to be indicated to evaluate for palpitations, then non-real time (off-line) monitoring devices such as extended (48 hour) Holter monitoring or off-line event monitoring should be sufficient for the identification of both symptomatic and asymptomatic dysrhythmias including atrial fibrillation. Continuous off-line 24-to-48 hour Holter monitoring should be able to effectively identify symptomatic or asymptomatic dysrhythmias that occur frequently. Likewise, self-activated non-real time and non-continuous monitoring devices (event recorders) should be effective at recording symptomatic dysrhythmias during less frequent symptoms.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
How to use this in your appeal
These are outcomes from California’s external review program — an independent physician panel that binds the insurer. Every state has an equivalent process, and internal appeals succeed even more often. Cite the outcome record for Wearable Cardio Defibwhen you appeal: reviewers routinely find that denials like yours didn’t hold up.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.